Brokerages Set Hologic, Inc. (NASDAQ:HOLX) PT at $87.27

Shares of Hologic, Inc. (NASDAQ:HOLX) have earned an average rating of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat reports. Five analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $87.50.

Several equities research analysts have weighed in on the stock. Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and lowered their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Mizuho raised their price target on shares of Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. Evercore ISI raised their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a report on Friday, August 16th.

Hologic Price Performance

Shares of HOLX opened at $79.81 on Tuesday. The company has a market cap of $18.63 billion, a price-to-earnings ratio of 40.72, a price-to-earnings-growth ratio of 2.89 and a beta of 0.98. Hologic has a twelve month low of $64.02 and a twelve month high of $84.67. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The company has a 50 day moving average of $81.06 and a two-hundred day moving average of $77.58.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.04. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. Hologic’s revenue was up 2.7% compared to the same quarter last year. During the same period last year, the firm earned $0.93 earnings per share. As a group, analysts predict that Hologic will post 4.09 earnings per share for the current fiscal year.

Insider Buying and Selling at Hologic

In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the transaction, the insider now owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the transaction, the insider now owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares of the company’s stock, valued at $310,415.85. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,280 shares of company stock valued at $1,469,973. Corporate insiders own 1.75% of the company’s stock.

Institutional Trading of Hologic

Institutional investors have recently modified their holdings of the stock. Cetera Investment Advisers grew its position in shares of Hologic by 188.9% in the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after purchasing an additional 13,380 shares during the period. Nordea Investment Management AB boosted its position in Hologic by 1.3% during the first quarter. Nordea Investment Management AB now owns 1,507,743 shares of the medical equipment provider’s stock worth $116,797,000 after acquiring an additional 19,680 shares during the last quarter. Clearbridge Investments LLC boosted its position in Hologic by 51.4% during the first quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock worth $40,430,000 after acquiring an additional 176,006 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Hologic by 18.3% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,184,427 shares of the medical equipment provider’s stock worth $170,297,000 after acquiring an additional 338,212 shares during the last quarter. Finally, Mediolanum International Funds Ltd acquired a new position in Hologic during the first quarter worth about $1,793,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.